Research conducted by an international team of scientists discovered a mechanism that leads to Herceptin resistance, representing a significant clinical obstacle to successfully treating HER2-positive breast […]
Baricitinib demonstrates sustained long-term efficacy in patients with moderate-to-severe atopic dermatitis, according to a study published online May 12 in JAMA Dermatology.